Literature DB >> 28366685

Increased risk of active tuberculosis after cancer diagnosis.

Dennis F Simonsen1, Dóra K Farkas2, Charles R Horsburgh3, Reimar W Thomsen2, Henrik T Sørensen4.   

Abstract

BACKGROUND: Cancer may increase risk of active tuberculosis but evidence is sparse. We therefore examined tuberculosis risk in patients with incident cancer using Danish nationwide medical databases.
METHODS: We conducted a matched follow-up study comparing risk of active tuberculosis in cancer-exposed individuals to that in a general population comparison cohort, matched on gender, age, and country of origin, in different follow-up intervals using Cox regression.
FINDINGS: We identified 290,944 patients with incident cancer and 871,147 matched comparison cohort members during 1 January, 2004-30 November, 2013. After adjusting for comorbidities, the overall adjusted hazard ratio (aHR) for tuberculosis among cancer patients was 2.48 (95% confidence interval [CI]: 1.99-3.10). The highest tuberculosis risks were observed following cancers of the aerodigestive tract (aHR = 8.12; 95% CI: 4.33-15.22), tobacco-related cancers (aHR = 5.01; 95% CI: 3.37-7.44), and hematological cancers (aHR = 4.88; 95% CI: 2.27-10.48). Tuberculosis risk was highly elevated within the first year after cancer diagnosis (aHR = 4.14; 95% CI: 2.88-5.96), with a 6.78-fold increased aHR for cancer patients receiving cytostatics or radiotherapy. Beyond five years of observation, the overall aHR for tuberculosis remained at 2.66 (95% CI: 1.22-5.81).
INTERPRETATION: Cancer is a clinical predictor for increased risk of active tuberculosis, probably related to decreased infection barriers, immunosuppression, and shared risk factors.
Copyright © 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Cohort study; Epidemiology; Immunosuppression; Tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28366685     DOI: 10.1016/j.jinf.2017.03.012

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  6 in total

Review 1.  Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations.

Authors:  Amalia Anastasopoulou; Dimitrios C Ziogas; Michael Samarkos; John M Kirkwood; Helen Gogas
Journal:  J Immunother Cancer       Date:  2019-09-04       Impact factor: 13.751

2.  Risk of active tuberculosis in migrants diagnosed with cancer: a retrospective cohort study in British Columbia, Canada.

Authors:  Divjot S Kumar; Lisa A Ronald; Kamila Romanowski; Caren Rose; Hennady P Shulha; Victoria J Cook; James C Johnston
Journal:  BMJ Open       Date:  2021-03-02       Impact factor: 2.692

Review 3.  Sarcoidosis and Cancer: A Complex Relationship.

Authors:  Thomas El Jammal; Michel Pavic; Mathieu Gerfaud-Valentin; Yvan Jamilloux; Pascal Sève
Journal:  Front Med (Lausanne)       Date:  2020-11-24

4.  The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis.

Authors:  Mei Chai; Qingming Shi
Journal:  BMC Cancer       Date:  2020-11-19       Impact factor: 4.430

5. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

6.  Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study.

Authors:  Seongman Bae; Ye-Jee Kim; Min-Ju Kim; Jwa Hoon Kim; Sung-Cheol Yun; Jiwon Jung; Min Jae Kim; Yong Pil Chong; Sung-Han Kim; Sang-Ho Choi; Yang Soo Kim; Sang-Oh Lee
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.